As the timeline shortens for Albert Bourla to take over the reins of Pfizer from Chief Executive Officer Ian Read, the company has released details of the new senior management team that will continue to lead the company forward.
As the timeline shortens for Albert Bourla to take over the reins of Pfizer from Chief Executive Officer Ian Read, the company has released details of the new senior management team that will continue to lead the company forward.
Bourla takes over from Reid on Jan. 1 after he helmed the company for the past eight years. Bourla said Pfizer is at a pivotal moment in its history, but noted that the company has a strong portfolio of marketed products, as well as a deep pipeline that will help accelerate revenue growth. With that in mind, Bourla began to shape the team that will support his tenure at the helm of the pharmaceutical giant.
The new leadership team includes:
- Frank D’Amelio – Serving as both chief financial officer and head of global supply and business operations, D’Amelio will also head up manufacturing operations for the company’s global supply chain.
- Mikael Dolsten – The new chief medical officer for Pfizer, Dolsetn will also oversee the company’s worldwide research and development efforts.
- Michael Goettler - Goettler will lead the company’s established medicines business that will operate as an autonomous, stand-alone unit within Pfizer.
- Angela Hwang – Currently serving as group president of Pfizer Innovative Medicines, Hwang will become the group president of Pfizer’s science-based Innovative business responsible for the entire portfolio of innovative medicines.
- Rady Johnson – Johnson will continue to serve Pfizer in the role of the company’s chief compliance officer.
- Doug Lankler – He will continue in his role as the company’s General Counsel.
- Freda Lewis-Hall –Lewis-Hall will take on the role of Pfizer’s Chief Patient Officer. In this role, Lewis-Hall will deploy the company’s resources to advocate on behalf of all patients who rely on Pfizer to deliver new therapies and vaccines.
- Rod MacKenzie – As chief development officer, Pfizer said MacKenzie will expand his responsibilities to include Pfizer’s regulatory affairs function in addition to all late-stage development activities.
- Dawn Rogers – Rogers will continue to lead the Human Resources team as chief human resources Officer.
- Sally Susman – Susman will continue to serve Pfizer ad the company’s chief corporate affairs officer.
- John Young – Chief Business Officer John Young will assume a new role. He will be responsible for strategy, business development, portfolio management and valuation activities; business analytics and global commercial operations. Also, he will oversee patient and health impact. Pfizer’s Consumer Healthcare business will report to Young.
Additionally, starting Jan. 1, Pfizer will add a chief digital officer to support the growing strategic importance of deploying digital technologies in research, discovery and business processes. Pfizer said Lidia Fonseca will join Pfizer’s Executive Leadership Team as chief digital and technology officer. Fonseca is currently the chief information officer at Quest Diagnostics. She previously held roles at Laboratory Corporation of America, Synarc and Philips Healthcare.
Pfizer noted that Kirsten Lund-Jurgensen, head of Pfizer global supply and Laurie Olson, head of strategy and commercial operations, will both retire effective Jan. 1, 2019.
“Given this opportunity to realize this accelerated growth potential, we are creating an executive team that has a proven record of success, an unwavering commitment to the patients we serve, and a clear value creation initiative. I look forward to working with these outstanding leaders to achieve the full potential of our pipeline and deliver our next stage of growth,” Bourla said in a statement.
